1. Introduction {#s0005}
===============

Despite increasing capabilities in technology and analytic perspectives, translational researchers still face familiar challenges in generating successful trials and studies ([@bb0005]). Both in the US and internationally, slow recruitment and limited retention of research participants can hinder the research process ([@bb0010], [@bb0015]; [@bb0020]). Participation and engagement are further limited within some marginalized socioeconomic or cultural groups ([@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040]). In parallel, human subjects\' research regulations in the U.S. and E.U. pose ethical and public relations challenges ([@bb0045], [@bb0050]), with many researchers and institutions preferring to use de-identified datasets to limit responsibilities and liabilities. Against these common research challenges are evolving new modes of data sharing and collaboration, including research networks and increasingly coordinated access to large-scale resources such as biobanks or clinical data warehouses. These innovations also increase the complexity of coordination, accountability, preference management, and researcher--participant communication ([@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080], [@bb0085]). The ability to leverage communications technologies such as social media may ameliorate some of the traditional roadblocks to broad patient participation in health care ([@bb0090]), and similar approaches provide new models for engaging participants in the research process and facilitating researcher--participant collaboration. In clinical settings, decision aids have been evolving to support patients\' self-education and decision support as components of their participation in therapeutic paths, and these methods can now also play a part in research ([@bb0095]). As these technologies and challenges intersect, a range of public/private participant-centric initiatives illustrate how information tools can expedite translational research. We highlight four emerging types of initiatives that illustrate evolving approaches of participant engagement and the use of informatics-based tools to expedite translational research.

2. What are patient centric-initiatives? {#s0010}
========================================

Participant-centric initiatives (PCI) are tools, programs, and projects that empower participants to engage in the research process and, in many cases, can differentiate between a range of diverse preferences and needs. Although current U.S. and E.U. human subjects\' regulations permit secondary research on de-identified data and biosamples without further participant contact or consent ([@bb0050]), cautionary tales demonstrate that people feel that they are marginalized if they are excluded from the research process ([@bb0080], [@bb0085]). For example, some research participants are not concerned about what happens to biosamples that have been collected from them for research, yet many participants have concerns about their lack of involvement in data sharing for secondary research use ([@bb0090], [@bb0105], [@bb0110]). Diverse preferences need dynamic tools to manage them, and one-size fits all approaches such as waivers of consent or "broad consent" are increasingly under significant critique ([@bb0115], [@bb0120], [@bb0125]). PCI facilitate opt-in and opt-out approaches, where participants can make enquiries about their level of engagement in studies.

Given this complex social climate of regulatory challenges, participant desire for greater control, and advancing scientific needs, our current regulations may provide a baseline for research practice, above which methods that support greater connection with participants may be beneficial. PCI offer the potential to communicate with participants and in some instances, mediate participants\' active control and choice within diverse research contexts. Conceptually, PCI facilitate a shift from a negative right to privacy, where researchers protect identity by promising anonymity or de-identification, to a positive right to privacy, where participants are given active control over who sees their data and in what contexts ([@bb0130]). Although further research is needed to demonstrate the impact of increased participant control afforded by PCI on recruitment and retention, we can anticipate that the shift to more participant control will address some concerns expressed by privacy advocates about data used for research ([@bb0105]). Furthermore, where some disenfranchised groups have been historically mistreated at the hands of researchers, the hypothesis is that increased control and enhanced communication opportunities will improve transparency to the point of encouraging participation ([@bb0025], [@bb0030], [@bb0035], [@bb0040]).

A growing evidence base of patient-centric health initiatives, decision-support research ([@bb0110]), and participant managed research enterprises provides a range of alternative models from which to learn ([@bb0140], [@bb0145], [@bb0150], [@bb0155], [@bb0160], [@bb0165]). In two recent international "state of the science" meetings, emerging tools for participant-centered informatics approaches used in research-based initiatives were discussed ([@bb0150], [@bb0155]). In light of these emerging tools, we created a framework to characterize four approaches utilized within the tools with some tools incorporating more than one approach ([Fig. 1](#f0005){ref-type="fig"}).

There are many PCI tools that directly contribute to research but which fall outside of the criteria of this paper because they focus primarily on empowering patients in their medical care. Examples include social networking tools like Inspire.com and TuDiabetes ([@bb0165]), and participant-driven survey databases, such as CureTogether.com. These tools contain large amounts of detailed personal data and represent a resource for researchers to discover new research questions, find potential participants, and analyze the effectiveness of treatments. However, these tools aim primarily to empower patients in their medical care rather than the research process. Our review is by no means exhaustive, but rather an analysis of promising initiatives that offer the research community several options for consideration.

2.1. Finding the engaged participant through intermediation: participant--researcher 'matchmaking' tools {#s0015}
--------------------------------------------------------------------------------------------------------

A range of potential factors may affect consideration of participation in research, including prior participation in research and existing relationships with researchers, involvement of trusted leaders, and trust in the organization ([@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040]). Although a majority of US residents (77%) say that they would consider becoming involved in a research trial, only 10% of those eligible to participate do so ([@bb0015]). Many are not aware of research opportunities (unpublished results, NWABR 2012). European residents vary considerably in consideration of contribution of data or samples to a biorepository for research purposes, with "93% of Icelanders and 82% of Norwegians could imagine providing information to a biobank, but only 25% of Latvians or 35% of Austrians are likely to do so" ([@bb0020]). Some common barriers to recruitment include lack of participant incentives, privacy concerns, complex and confusing consent forms, differences in cultural norms, and lack of public knowledge about the potential for participation. One possible solution is more active facilitation of connections between willing volunteers and searching researchers, and enhanced communication structures that support these potential relationships. Matchmaking tools do so by acting as intermediators that draw together researchers and participants. For example, participant-driven clinical registries, such as ResearchMatch.org, TrialX.com, and EmergingMed.com enable willing volunteers to enter personal information (e.g., age, sex, conditions) and use this information to find researchers in need as well as clinical trials seeking participants.

Currently, the effectiveness of such registry approaches depends upon the study type ([@bb0170]). Traditional recruitment methods, such as direct use of hospital data warehouses, are still beneficial particularly if the participant inclusion criteria are well defined or the study requires complex exclusion criteria. For example, a study may require participants to be diabetic, with hemoglobin A1C values between 6.5% and 8.0%, have pre-existing ischemic vascular disease, not use insulin therapy, and have a certain requirement for glomerular filtration rate. At present it will be difficult for participant-driven clinical registries to match this level of specificity, though tools like EmergingMed.com, are addressing this problem by offering defined and structured data definition and query options for cancer patients and researchers. Continued technological advancement and wide-scale adoption by researchers and volunteers alike are contributing to richer data resources, and are demonstrating the potential of such matchmaking tools for overcoming recruitment bottlenecks in limited domains, though a comprehensive evaluation of the effectiveness of these tools across a range of demographic and disease types is still nascent.

2.2. Engagement through direct participant benefits: 'Direct-to-consumer' tools {#s0020}
-------------------------------------------------------------------------------

Direct-to-consumer (DTC) tools offer individuals highly personalized information as a proposed direct benefit of participation. For example, established web-based DTC genetic testing companies, such as 23andMe.com or deCODEme.com seek to empower and promote identity perception for individuals by supplying them with personal genotype and phenotype information that may inform their personal health decisions ([@bb0175]). The social interactions between DTC companies and their customers are not without controversy, as the promise of this form of consumer-focused health decision making has to date managed to avoid either the predicted dire consequences of a excessively worried public, or the proposed swell of empowered and activated patients ([@bb0175], [@bb0180]). What the DTC companies have enabled beyond personalized information is the increased ability to facilitate participation in research. The research arm of 23andMe, '23andWe', notifies members of research opportunities enabled through more personalized matching of studies than ResearchMatch through an extensive set of structured surveys about their phenotypic traits. By connecting those self-reports to corresponding genotypes, 23andWe can produce publishable study results, and within days can verify other published results ([@bb0185], [@bb0190]). To help drive their research arm, 23andMe created condition-specific member communities (e.g., Parkinson\'s, sarcoma, pregnant women). By joining, members receive free genetic testing and involvement in the community forum. For example, the "Roots into the future" community is an up-and-coming community that offers 10,000 African Americans free genetic testing in return for completing surveys. 23andWe\'s model leverages individuals\' willingness to participate in research and rewards their participation with information people value. Given the amount of genetic information that 23andMe can gather through this approach to participant engagement, it is reasonable to assume that they have the potential to produce many more substantial findings.

Like 23andMe, the health social network PatientsLikeMe.com started as an organization that provided a service to people curious about their health and frustrated with the slow progress of traditional research. PatientsLikeMe.com has a substantial research arm and has great potential to conduct studies faster and cheaper than existing models ([@bb0185]). For example, analysis of data reported by people with amyotrophic lateral sclerosis (ALS) who experimented with lithium carbonate reached the same conclusion as traditional randomized trials ([@bb0190]), indicating the potential for such communities to conduct valuable studies. PatientsLikeMe.com also offers a comprehensive clinical trial finder and various health tracking tools, making the site a rich source of data. PatientsLikeMe.com asks all researchers to first contact their partnership team before allowing researchers to use the data for research or to use the site to recruit participants in their studies. Once the partnership team gives permission, researchers can specifically search for users who fit their study criteria. The referral rates are high, making PatientsLikeMe.com an attractive and viable option for populating studies.

2.3. Participant control through choices: tools for 'dynamic negotiation' between researchers and participants {#s0025}
--------------------------------------------------------------------------------------------------------------

DTC companies seek to offer something that many research institutions are unable to provide - a user-friendly interface that gives users of a range of literacy and education levels descriptive, personalized and easily accessible information. However, at present most DTC users pay for the service, and in doing so, fuel research efforts of the parent companies offering these services. Although most researchers cannot individually offer the same usability and customer support amenities as 23andMe.com, they are increasingly able to offer participants greater levels of choice and control, as well as manage a diverse range of participant preferences. The company Private Access (privateaccess.info) is one such platform that seeks to provide participants with substantial control over the uses of their data in research ([@bb0195]). The platform allows researchers to search for potential study participants with great specificity because participants who use Private Access enter their entire personal health records, and have control over both individual portions of their personal health records as well as the scope of researchers and research groups that the data is visible to. Researchers can use Private Access to recruit participants, access this private data by being granted "private access" by the participants, and use the data in the records of recruited participants in applicable research projects.

Private Access uses this dynamic negotiation approach to moderate patient involvement in research repositories. The traditional practice of entering data into repositories often requires participants\' broad consent to authorize secondary use of their anonymized or de-identified data. Although it may be impossible for participants to fully know all potential future studies in which their data could be used, refusal to agree to such broad use thus renders secondary usage of their data an all or nothing decision ([@bb0050]). Private Access arguably overcomes this bottleneck by permitting individual control over privacy and data sharing, much like social sharing tools like Facebook.com. Some participants may choose to set liberal privacy settings, permitting any researcher access to their data in full for screening and eligibility purposes, while others may request to be contacted about study eligibility after giving access permission on a case-by-case basis. By giving participants this dynamic control, Private Access supports broad consent, if that is what an individual prefers, but it also gives participants the opportunity to choose the access level with which they are most comfortable over time. It should be noted that much like Facebook and other social-networking sites, the definition of what is personally and culturally appropriate to share is an evolving discussion and one that is likely to vary from person to person. Tools such as Private Access, or the open-source Indivo (indivohealth.org), can be tailored to provide culturally specific information or utilize trusted community leaders as "guides" through the decisions involved in selecting preferences. Data is emerging now regarding how tools such as these facilitate participant participation.

2.4. Public engagement through citizen science: direct participant involvement tools {#s0030}
------------------------------------------------------------------------------------

Increased public awareness of large volunteer registries, such as the Love/Avon Army of women (armyofwomen.org) or Inspire 2 Live (inspire2live.com) can be considered a minimal form of public engagement in the research process. Towards the other end of the spectrum lies Genomera.com, a company that seeks to empower and engage the public in research by giving them the opportunity to be 'citizen scientists' who can design, conduct, and analyze their own studies ([@bb0200]). Members of Genomera.com can develop their own study designs (i.e., study creator), participate in the study themselves, and post procedures for other community members to participate in their study. Study participants then send their results to the study creator for analysis. The openness of this community enables participants to be recruited and studies to be completed much quicker than the traditional research process.

Given the established conventions for peer review and controlled research, the likelihood of the citizen scientists at Genomera.com having their results published in scientific journals is presently slim. However, with widespread adoption of this approach, validation of methods, the possibility of finding significant results, or creating methods that can be replicated in other studies is possible. Furthermore, such citizen science approaches are challenging existing paradigms about accepted standards in research, finding their own distribution channels outside of traditional dissemination strategies ([@bb0205]). Efforts, such as Genomera.com, demonstrate the desire for people to play a larger role in research. Whether through educating participants about studies they participate in, returning study results ([@bb0210]), or answering participants\' questions, participants can become more involved ([@bb0215]). Involving participants could increase the likelihood of future participation, adherence to study protocols, or sharing positive research experiences with others.

3. Conclusion {#s0035}
=============

There are widespread changes occurring internationally in health care, and all face common challenges of effective leverage of information technology, the need for accurate clinical and health data, and the need for privacy protections ([@bb0005], [@bb0220], [@bb0225]). The research enterprise can utilize similar developments in order to keep up with changing socio-cultural context that requires more engaged research participation to be successful. If decisions are made and practices are built without due diligence to public opinion, then the string of inefficiencies and ethical questions will unnecessarily grow. We have observed resources destroyed due to of lack of appropriate public engagement ([@bb0230]). We should look not only to public opinion, but also to the empowered public by facilitating their engagement in the research process as key stakeholders. Recruiting participants, protecting their privacy, and ensuring informed consent should not be viewed as burdensome bottlenecks, but rather as opportunities to engage, inform, and benefit the ultimate end-user of all research, the public.

Using PCI in research is one approach to overcome these challenges by leveraging new communication and facilitation modes increasingly available through the on-line economy. From the informatics-based initiatives we have presented, to the great successes of participant-centered organizations like Love\'s Army of Women and Genetic Alliance, to participant-driven social networking sites, the possibilities of an empowered public are starting to be realized. Data are needed in a variety of settings to test whether and how PCI can facilitate and sustain research participation across populations, particularly those with less access to web-based technologies and who may benefit the most. If we keep lessons learned from community-based research, minority recruitment, decision support, and other innovations, we can meet the goal of an active and invested community of research participants. With the current initiatives already in development and use, we have crossed an important threshold of feasibility testing and can now move into efficacy and effectiveness studies. Research groups and funders can begin to make the choice to utilize these tools and study the process along the way.
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